Moonlake Immunotherapeutics (MLTX)

$14.99 +1.64 (12.32%)
Market Cap 804.17M
Revenue (ttm) 0.00
Net Income (ttm) -118.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.25
Volume 4,052,039
Avg Vol 6,164,544
Day's Range N/A - N/A
Shares Out 64.23M
Stochastic %K 55%
Beta 1.21
Analysts Sell
Price Target $14.61

Company Profile

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Industry: Biotechnology
Sector: Healthcare
Phone: 41 415108022
Address:
Dorfstrasse 29, Zug, Switzerland
AmilOrdep
AmilOrdep Dec. 4 at 9:38 PM
🚨 FDA is considering defaulting to ONE clinical trial for drug approvals instead of two. This could dramatically speed up timelines & cut development costs for biotech companies. $MLTX stands to benefit significantly from this policy shift. 👉https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/ #FDA #biotech #drugdevelopment #moonlake
0 · Reply
InsuranceSalesman
InsuranceSalesman Dec. 4 at 9:36 PM
$MLTX Some profit-taking by swing traders eod was expected but very interesting from an options standpoint. Whales with deep pockets either speculating or in-the-know that there are talks underway for a buyout 300 to 400% above current price. Will hold this for a while and see.
0 · Reply
Bigbadjohn89
Bigbadjohn89 Dec. 4 at 9:36 PM
$MLTX $BMEA
0 · Reply
AmilOrdep
AmilOrdep Dec. 4 at 9:35 PM
$MLTX 🚨 FDA is considering defaulting to ONE clinical trial for drug approvals instead of two. This could dramatically speed up timelines & cut development costs for biotech companies. $MLTX stands to benefit significantly from this policy shift. 👉https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/ #FDA #biotech #drugdevelopment #moonlake
0 · Reply
resistancebreakers
resistancebreakers Dec. 4 at 9:33 PM
$MLTX 🔥
0 · Reply
MzzO
MzzO Dec. 4 at 9:27 PM
$MLTX good job today
0 · Reply
slickinvest
slickinvest Dec. 4 at 9:25 PM
$MLTX give me that Merck news buyout
1 · Reply
Joe_90_
Joe_90_ Dec. 4 at 9:12 PM
$MLTX
1 · Reply
Bigbadjohn89
Bigbadjohn89 Dec. 4 at 9:09 PM
$BMEA I’ve been so focused on $MLTX I didn’t realize this was running today. In with 100k+ shares. Let’s get it
1 · Reply
Bikenchef73
Bikenchef73 Dec. 4 at 9:08 PM
$MLTX This and $BMEA are looking good and solid. @Creisi
1 · Reply
Latest News on MLTX
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

Dec 4, 2025, 3:01 PM EST - 1 hour ago

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 4, 2025, 10:52 AM EST - 5 hours ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

Dec 4, 2025, 9:00 AM EST - 7 hours ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

Dec 3, 2025, 3:05 PM EST - 1 day ago

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 3, 2025, 7:46 AM EST - 1 day ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

Dec 2, 2025, 5:29 PM EST - 1 day ago

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

CPTN

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

Dec 2, 2025, 5:25 PM EST - 1 day ago

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 1, 2025, 5:52 PM EST - 2 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Dec 1, 2025, 3:18 PM EST - 3 days ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Voya MidCap Opportunities Strategy Q3 2025 Portfolio Review

Dec 1, 2025, 12:26 PM EST - 3 days ago

Voya MidCap Opportunities Strategy Q3 2025 Portfolio Review

APP FIX KTOS TW VRSK

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 30, 2025, 7:45 AM EST - 4 days ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

Nov 28, 2025, 5:50 PM EST - 5 days ago

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

Biotech Fund Reveals $15 Million MoonLake Exit After Stock's 90% Crash

Nov 28, 2025, 3:45 PM EST - 6 days ago

Biotech Fund Reveals $15 Million MoonLake Exit After Stock's 90% Crash

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

Nov 27, 2025, 2:15 PM EST - 7 days ago

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Nov 24, 2025, 8:36 AM EST - 10 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 24, 2025, 6:08 AM EST - 10 days ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Nov 20, 2025, 2:18 PM EST - 14 days ago

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

5AM Venture Bails on MoonLake After a Brutal Year: Here's What Stands Out

Nov 18, 2025, 1:55 PM EST - 16 days ago

5AM Venture Bails on MoonLake After a Brutal Year: Here's What Stands Out

MoonLake: Ignore The Panic, Catch The Upside

Nov 18, 2025, 12:33 AM EST - 16 days ago

MoonLake: Ignore The Panic, Catch The Upside

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 14, 2025, 6:08 AM EST - 20 days ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 8:15 AM EST - 24 days ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 10, 2025, 6:06 AM EST - 24 days ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:11 AM EST - 4 weeks ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

Nov 1, 2025, 7:08 AM EDT - 4 weeks ago

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Oct 28, 2025, 9:51 AM EDT - 5 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman

Oct 14, 2025, 12:03 PM EDT - 7 weeks ago

MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman

MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money

Oct 10, 2025, 8:18 AM EDT - 7 weeks ago

MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money

MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

Oct 9, 2025, 3:18 PM EDT - 2 months ago

MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

AmilOrdep
AmilOrdep Dec. 4 at 9:38 PM
🚨 FDA is considering defaulting to ONE clinical trial for drug approvals instead of two. This could dramatically speed up timelines & cut development costs for biotech companies. $MLTX stands to benefit significantly from this policy shift. 👉https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/ #FDA #biotech #drugdevelopment #moonlake
0 · Reply
InsuranceSalesman
InsuranceSalesman Dec. 4 at 9:36 PM
$MLTX Some profit-taking by swing traders eod was expected but very interesting from an options standpoint. Whales with deep pockets either speculating or in-the-know that there are talks underway for a buyout 300 to 400% above current price. Will hold this for a while and see.
0 · Reply
Bigbadjohn89
Bigbadjohn89 Dec. 4 at 9:36 PM
$MLTX $BMEA
0 · Reply
AmilOrdep
AmilOrdep Dec. 4 at 9:35 PM
$MLTX 🚨 FDA is considering defaulting to ONE clinical trial for drug approvals instead of two. This could dramatically speed up timelines & cut development costs for biotech companies. $MLTX stands to benefit significantly from this policy shift. 👉https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/ #FDA #biotech #drugdevelopment #moonlake
0 · Reply
resistancebreakers
resistancebreakers Dec. 4 at 9:33 PM
$MLTX 🔥
0 · Reply
MzzO
MzzO Dec. 4 at 9:27 PM
$MLTX good job today
0 · Reply
slickinvest
slickinvest Dec. 4 at 9:25 PM
$MLTX give me that Merck news buyout
1 · Reply
Joe_90_
Joe_90_ Dec. 4 at 9:12 PM
$MLTX
1 · Reply
Bigbadjohn89
Bigbadjohn89 Dec. 4 at 9:09 PM
$BMEA I’ve been so focused on $MLTX I didn’t realize this was running today. In with 100k+ shares. Let’s get it
1 · Reply
Bikenchef73
Bikenchef73 Dec. 4 at 9:08 PM
$MLTX This and $BMEA are looking good and solid. @Creisi
1 · Reply
__GoldingSteers
__GoldingSteers Dec. 4 at 9:05 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $NVVE $DEFT $MLTX $GSAT Reports
0 · Reply
diegosan21
diegosan21 Dec. 4 at 9:03 PM
$MLTX A Nice round number to close
0 · Reply
Bigpapa46
Bigpapa46 Dec. 4 at 9:02 PM
$MLTX 50k share in the last minute and it looks like it closed at $15.00- Nice day with many more to come
0 · Reply
Bigbadjohn89
Bigbadjohn89 Dec. 4 at 9:01 PM
$MLTX strong close
0 · Reply
Bigpapa46
Bigpapa46 Dec. 4 at 8:58 PM
$MLTX The last 10 minutes trading the lemmings are falling over each other lol
0 · Reply
slickinvest
slickinvest Dec. 4 at 8:58 PM
$MLTX
0 · Reply
archerpound
archerpound Dec. 4 at 8:56 PM
$MLTX $PATH $QCLS Breakthrough confirmed https://www.linkedin.com/posts/kevin-josh-297b1a398_%F0%9D%97%AA%F0%9D%97%B2%F0%9D%97%B9%F0%9D%97%B0%F0%9D%97%BC%F0%9D%97%BA%F0%9D%97%B2-%F0%9D%98%81%F0%9D%97%BC-%F0%9D%97%BC%F0%9D%98%82%F0%9D%97%BF-%F0%9D%97%B1%F0%9D%97%AE%F0%9D%98%86-%F0%9D%98%81-activity-7402374152130547712-Bout?utm_medium=ios_app&rcm=ACoAAGGymhMB9MOfYmf_ttSPmCS1s9Qal5wRCTA&utm_source=social_share_send&utm_campaign=copy_link
0 · Reply
Bigpapa46
Bigpapa46 Dec. 4 at 8:56 PM
$MLTX over 400k in volume so far in the last 30 minutes
0 · Reply
slickinvest
slickinvest Dec. 4 at 8:55 PM
$MLTX
0 · Reply
signaljumper
signaljumper Dec. 4 at 8:53 PM
$MLTX Up near 100% since Report released Ready the Report for free there are also other Reports released https://www.patreon.com/posts/140515589?utm_campaign=postshare_creator&utm_content=android_share
1 · Reply
InsuranceSalesman
InsuranceSalesman Dec. 4 at 8:53 PM
$MLTX Wow! Apparently other whales smell opportunity when another whale spends $250K on calls 30% out of the money that expire in 6 weeks.
0 · Reply
FuhqAgentOrange
FuhqAgentOrange Dec. 4 at 8:49 PM
$MLTX
0 · Reply